Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPatel, Aarti-
dc.contributor.authorKimura, Ryoichi-
dc.contributor.authorFu, Wen-
dc.contributor.authorSoudy, Rania-
dc.contributor.authorMacTavish, David-
dc.contributor.authorWestaway, David-
dc.contributor.authorYang, Jing-
dc.contributor.authorDavey, Rachel A-
dc.contributor.authorZajac, Jeffrey D-
dc.contributor.authorJhamandas, Jack H-
dc.identifier.citationMolecular neurobiology 2021-10; 58(10): 5369-5382en
dc.description.abstractBased upon its interactions with amyloid β peptide (Aβ), the amylin receptor, a class B G protein-coupled receptor (GPCR), is a potential modulator of Alzheimer's disease (AD) pathogenesis. However, past pharmacological approaches have failed to resolve whether activation or blockade of this receptor would have greater therapeutic benefit. To address this issue, we generated compound mice expressing a human amyloid precursor protein gene with familial AD mutations in combination with deficiency of amylin receptors produced by hemizygosity for the critical calcitonin receptor subunit of this heterodimeric GPCR. These compound transgenic AD mice demonstrated attenuated responses to human amylin- and Aβ-induced depression of hippocampal long-term potentiation (LTP) in keeping with the genetic depletion of amylin receptors. Both the LTP responses and spatial memory (as measured with Morris water maze) in these mice were improved compared to AD mouse controls and, importantly, a reduction in both the amyloid plaque burden and markers of neuroinflammation was observed. Our data support the notion of further development of antagonists of the amylin receptor as AD-modifying therapies.en
dc.subjectAlzheimer’s diseaseen
dc.subjectAmylin receptoren
dc.subjectAmyloid-β proteinen
dc.subjectCalcitonin receptoren
dc.subjectLong-term potentiationen
dc.subjectSpatial memoryen
dc.titleGenetic Depletion of Amylin/Calcitonin Receptors Improves Memory and Learning in Transgenic Alzheimer's Disease Mouse Models.en
dc.typeJournal Articleen
dc.identifier.journaltitleMolecular Neurobiologyen
dc.identifier.affiliationCenter for Liberal Arts and Sciences, Sanyo-Onoda City University, Yamaguchi , 756-0884, Japanen
dc.identifier.affiliationFaculty of Pharmacy, Cairo University, Giza, Egypten
dc.identifier.affiliationDepartment of Biochemistry, University of Alberta, Edmonton, AB, T6G 2H7, Canadaen
dc.identifier.affiliationCentre for Prions and Protein Folding Diseases, University of Alberta, Edmonton, AB, T6G 2M8, Canadaen
dc.identifier.affiliationMedicine (University of Melbourne)en
dc.identifier.affiliationDepartment of Medicine (Neurology), Neuroscience and Mental Health Institute, University of Alberta, Edmonton, AB, T6G 2S2, Canadaen
dc.identifier.pubmedid34312771-, Jeffrey D
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.openairecristype (University of Melbourne)-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Dec 8, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.